StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$2.98−0.11 (-3.56%)

Close on Nov 18, 2026Market cap $295.46MP/E –Yield –

X4 Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

X4 Pharmaceuticals's price to sales ratio was 35.7× on Nov 11, 2026, against 16.1× a year earlier. Over the last 3 years it ranged from 2.8× to 57.8×, with a median of 37.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202635.7×+18.0
2025Dec 31, 202517.6×−27.9
2021Apr 30, 202145.6×+10.6
2020Dec 31, 202034.9×−3.1
2019Dec 31, 201938.0×–

More X4 Pharmaceuticals figures

See a number that looks wrong?